SciSparc's NeuroThera launches Tourette syndrome trial site at Yale
The Phase IIb SCI-110 study now runs at three sites total: one in Connecticut, one in Germany, and one in Israel.
SEC filing
Latest
Wednesday, August 5
Eton licenses ASN-001 topical gel to expand infantile hemangioma portfolio
Eton Pharmaceuticals paid Auson Pharmaceuticals $3.0 million upfront for U.S. rights to ASN-001, a topical timolol gel, with an NDA targeted for the second half of 2027.
SEC filing
Summit Therapeutics starts Phase II/III bladder cancer trial for ivonescimab
HARMONi-GU1 will test ivonescimab plus enfortumab vedotin against pembrolizumab plus enfortumab vedotin in untreated advanced urothelial carcinoma, with site activations planned by Q4 2026.
SEC filing
NewAmsterdam reports positive CHMP opinion for obicetrapib, sets PREVAIL and RUBENS timelines
The company said an EMA committee backed marketing authorization for obicetrapib and its ezetimibe combination, while cash stood at $678.3 million as of June 30, 2026.
SEC filing
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underway
Second-quarter update details 88% viral suppression in hepatitis delta trial, Astellas collaboration progress, and $1.0 billion cash position.
SEC filing
ImageneBio reports Q2 2026 results as olevaprubart pipeline advances on schedule
The company kept its Phase 2b atopic dermatitis trial on track for fourth-quarter 2027 data and said cash on hand extends its runway into early 2028.
SEC filing
Mirum raises 2026 sales guidance, volixibat gets FDA breakthrough status for PSC
The company also disclosed the FDA wants a Phase 3 study before a volixibat NDA, pushing the target filing to the first half of 2027.
SEC filing
Protagonist posts Q2 2026 profit as ICOTYDE launch and rusfertide review advance
Protagonist reported $162.8 million net income for the quarter, driven by Takeda payments, while awaiting an FDA decision on rusfertide in August 2026.
SEC filing
Tenaya reports Q2 2026 results with new TN-201, TN-401 data and Alnylam upfront payment
Interim gene therapy data and a $10 million Alnylam payment accompany fourth-quarter 2026 regulatory update plans for both lead programs.
SEC filing
United Therapeutics files two rare pulmonary disease NDAs, sets sights on approvals in 2027
The company said it submitted new drug applications for ralinepag tablets in PAH and Nebulized Tyvaso in IPF, with more filings and organ program milestones expected by year end.
SEC filing
Arcutis posts Q2 2026 profit as ZORYVE sales climb, raises full-year guidance
The company reported $129.9 million in ZORYVE sales for the quarter and lifted 2026 revenue guidance to $525 million-$540 million.
SEC filing
Recursion posts Q2 2026 results, Genentech advances first neuroscience target
The company reported a narrower net loss, lower cash operating expense guidance, and a new early discovery milestone in its neuroscience collaboration with Roche and Genentech.
SEC filing
Charles River raises 2026 guidance on stronger DSA and Manufacturing performance
The contract research firm posted a GAAP loss per share in the second quarter but lifted its full-year revenue and non-GAAP EPS outlook after book-to-bill improved.
SEC filing
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer data
Xencor confirmed a 2027 registration-enabling study plan for XmAb819 in kidney cancer, a 2H27 primary endpoint for XmAb942 in ulcerative colitis, and new Alexion settlement terms.
SEC filing
Immuneering reports Q2 2026 results, MAPKeeper 301 dosing underway
The company reported 17.3 month median overall survival in a first-line pancreatic cancer study and said its Phase 3 trial has begun dosing patients, with cash extending into 2029.
SEC filing
BioAge reports Q2 2026 results, first patient dosed in Phase 2 QUELL-CV trial
The company also plans a second BGE-102 study in diabetic eye disease and reported $381.3 million in cash as of June 30.
SEC filing
Attovia Therapeutics prices $289 million IPO ahead of Nasdaq debut
The clinical-stage biotech sold 17 million shares at $17 to fund its IL-31 and IL-13 pipeline, with trading set to begin under the ticker "ATTO."
SEC filing
Adicet Bio pushes prula-cel Phase 1 update to Q3 2026, cites FDA talks on pivotal trial
The company also flagged a Q3 2026 regulatory filing for ADI-212 in prostate cancer and said cash should last into the second half of 2027.
SEC filing
Editas reports Q2 2026 results, plans Australia CTN filing for EDIT-401
The gene editing company said it is on track to submit a clinical trial application this month and expects a data update in early 2027.
SEC filing
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026
Arcus added three new clinical collaborations for its HIF-2α inhibitor casdatifan and said cash runway extends to at least the second half of 2028.
SEC filing
BNB Plus faces Nasdaq delisting determination, moves to OTCQB pending appeal
The company formerly known as Applied DNA Sciences received a Nasdaq delisting determination over the $1.00 bid price rule and is seeking review while its shares trade on OTCQB.
SEC filing
Schrodinger launches Bunsen AI co-scientist, raises 2026 drug discovery revenue outlook
The company reported second-quarter ACV growth of 27% and lifted its full-year drug discovery revenue guidance after an Ajax Therapeutics milestone payment.
SEC filing
BeOne Medicines reports Q2 2026 results, raises full-year revenue guidance
Positive MANGROVE data in mantle cell lymphoma, an FDA accelerated approval for BEQALZI, and a raised 2026 revenue outlook of $6.6–$6.8 billion highlight the update.
SEC filing
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2
The company cited new drug approvals and an expanded pipeline as it lifted its full-year Portfolio Receipts outlook to $3,400 million to $3,500 million.
SEC filing
Lilly raises 2026 revenue guidance to $85-87 billion on Mounjaro, Zepbound growth
Second-quarter revenue rose 48% to $23.0 billion as Lilly reported progress across its obesity, immunology, and oncology pipeline.
SEC filing
Revolution Medicines advances daraxonrasib NDA and reports new lung cancer combination data
FDA accepted the pancreatic cancer NDA and granted Breakthrough Therapy status in NSCLC as the company posted a $644.4 million quarterly net loss.
SEC filing
Vaxcyte reports Q2 2026 results, OPUS Phase 3 trials fully enrolled, initiates VAX-A1 Phase 1
OPUS-1 topline data are expected in Q4 2026, with OPUS-2, OPUS-3 and VAX-31 infant data to follow in the first half of 2027, alongside a new VAX-A1 Phase 1 start.
SEC filing
Arrowhead posts Phase 1/2a results for inhaled ARO-MMP7 in IPF trial
Emergent BioSolutions posts Q2 revenue surge but takes $191 million impairment, cuts 2026 outlook
The company reported 66% revenue growth on government biodefense contracts while announcing a restructuring plan and slashing its full-year revenue forecast by up to $85 million.
SEC filing
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updates
New chief executive takes over as company narrows 2026 revenue guidance and reports progress in DM1, FSHD and Huntington's disease programs.
SEC filing
Kymera moves up KT-621 atopic dermatitis data after fast enrollment
Faster-than-planned enrollment in the STAT6 degrader's Phase 2b trial pulls the readout forward to year-end 2026 and sets up an earlier Phase 3 start.
SEC filing
MannKind reports Q2 2026 results with pediatric Afrezza and Furoscix ReadyFlow approvals
MannKind said it hit three 2026 catalysts in the quarter, including FDA approvals for pediatric Afrezza and the Furoscix ReadyFlow autoinjector, plus positive nintedanib DPI Phase 1b data.
SEC filing
Exelixis Q2 2026 results detail zanzalintinib pipeline progress, narrows guidance
The FDA's PDUFA date for zanzalintinib in metastatic colorectal cancer remains December 3, 2026, as new trials advance and guidance tightens.
SEC filing
Verastem registers open-label extension study for avutometinib-defactinib in LGSOC
Tuesday, August 4
OnKure amends ATM prospectus, drops Form S-3 offering cap
OnKure Therapeutics said it is no longer subject to a rule limiting how much stock it can sell under its existing $100 million at-the-market program with Leerink Partners.
SEC filing
Larimar reports Q2 2026 update on nomlabofusp BLA, Phase 3 timing and cash
Larimar says FDA aligned on a rolling BLA path for nomlabofusp in Friedreich's ataxia and expects to start a global confirmatory Phase 3 study in the third quarter of 2026.
SEC filing
argenx registers Phase 3 trial of adimanebart in rare congenital myasthenic syndromes
Alkermes registers expanded access program for pediatric LYBALVI patients
BeOne Medicines registers Phase 1a/1b trial of RAS inhibitor BG-85738 in solid tumors
Monte Rosa registers Phase 2 trial pairing MRT-2359 with apalutamide in prostate cancer
Deciphera registers Phase 1 drug interaction study of vimseltinib with dabigatran
Boehringer Ingelheim completes IPF/PPF antifibrotic survey; BI 3822971 trial still recruiting
Theriva stockholders approve stock plan increase, other proposals at annual meeting
At its August 3, 2026 annual meeting, Theriva Biologics shareholders approved six proposals, including an increase in shares available under its 2020 Stock Incentive Plan.
SEC filing
Dianthus reports Phase 3 CIDP interim data and gMG trial start, $1.2 billion cash
Dianthus disclosed a 75% response rate in an interim look at Part A of its Phase 3 CIDP trial and said its Phase 3 gMG trial began in June, alongside second-quarter results dated August 4, 2026.
SEC filing
Processa Pharmaceuticals shareholders approve equity plan increase at 2026 annual meeting
All six director nominees were reelected and shareholders backed a 200,000-share expansion of the company's incentive plan, per an August 4 8-K filing.
SEC filing
Seres Therapeutics issues shares to former landlord to settle lease termination debt
Seres registered 103,520 shares for BMR-Sidney at $4.83 each, worth $500,001.60, as partial payment for ending its Sidney Research Campus lease.
SEC filing
Pacira reports Q2 2026 results, updates guidance after iovera° sale to Zimmer Biomet
Pacira closed its iovera° divestiture on July 31, advanced its PCRX-201 gene therapy program, and trimmed full-year revenue guidance to reflect the sale.
SEC filing
Eton Pharmaceuticals names Danka Radosavljevic as Chief Operating Officer
The appointment took effect July 31, 2026, elevating a longtime executive who has been with the company since 2017.
SEC filing
Jasper Therapeutics discloses $132 million private securities offering in SEC filing
A Form D filed August 4, 2026 shows Jasper Therapeutics sold $131,999,611 in equity securities to 40 investors under a Rule 506(b) exemption.
SEC filing